Cannabis Dosing for Crohn's Disease UK: Patient

Cannabis Dosing for Crohn’s Disease: A UK Patient Guide

Understanding Crohn’s Disease and IBD
Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes inflammation throughout the digestive tract, potentially affecting any part from the mouth to the anus. Characterised by pain, diarrhoea, weight loss, and fatigue, Crohn’s significantly impacts quality of life for the estimated 115,000 UK patients living with the condition.

Traditional treatment approaches focus on immunosuppressive medications and biological therapies. However, growing evidence suggests that cannabinoids—compounds found in cannabis—may offer complementary symptom management, particularly for inflammation, pain, and appetite loss. Many UK patients have sought medical cannabis as part of their treatment strategy, either alongside or as an alternative to conventional therapies.

The UK Prescribing Approach: Start Low, Go Slow

The “start low, go slow” principle is fundamental to UK cannabis prescribing practice. This conservative approach reflects the current evidence base and individual variation in patient response. Rather than jumping to higher doses, treatment begins at minimal effective doses and increases gradually based on individual tolerance and therapeutic response.

This methodology serves several purposes: it minimises potential side effects, allows patients to identify their optimal dose, reduces the risk of adverse interactions with other medications, and builds confidence in using cannabis-based medicines. UK prescribers, including gastroenterologists and specialist cannabis clinicians, typically follow this protocol closely.

For information about getting a cannabis prescription in the UK, consult with your healthcare provider about whether medical cannabis may be suitable for your circumstances.

Typical Dose Ranges for Crohn’s Disease

Cannabis-based products for medical use in the UK typically contain varying ratios of CBD (cannabidiol) and THC (tetrahydrocannabinol). The appropriate dose depends on the specific product, the patient’s medical history, concurrent medications, and individual response.

CBD-dominant products: These often start at 10-20mg daily, divided into two doses. Doses may gradually increase to 50-100mg daily or higher, depending on symptom response and tolerability. CBD is generally well-tolerated with minimal psychoactive effects.

Balanced CBD:THC products: A common starting dose might be 2.5mg THC and 2.5mg CBD, taken once or twice daily. This may increase by similar increments every 3-7 days to a target range of 5-10mg THC and 5-10mg CBD daily, or higher if well-tolerated.

THC-dominant products: These are typically reserved for specific symptoms and started at very low doses (0.5-1mg THC). Most patients find therapeutic benefit at 2-5mg THC daily, though some require higher doses.

Individual variation is significant. Some patients respond to lower doses whilst others require substantially more. Your prescriber will guide dose adjustments based on your specific response.

Routes of Administration

The route of administration significantly affects onset time, duration, and intensity of effects. For Crohn’s disease patients, certain routes are preferred over others.

Oil tinctures: Sublingual oils offer rapid onset (15-30 minutes) and moderate duration (4-6 hours). This route allows flexible dosing and is popular amongst UK patients. Oils provide consistent dosing when measured carefully.

Capsules: Encapsulated products provide precise dosing and convenience. Onset is slower (45 minutes to 2 hours) due to gastrointestinal absorption, but effects last longer (6-8 hours). This makes capsules ideal for symptom management throughout the day.

Smoking and inhalation: These routes are generally avoided in Crohn’s disease management. Smoking irritates the already-inflamed digestive tract and respiratory system. Vaping is sometimes used but remains secondary to oral routes in UK clinical practice.

Rectal suppositories: Whilst available, suppositories bypass first-pass metabolism but are less commonly prescribed. They may be considered for patients with severe malabsorption or those unable to tolerate oral administration.

Titration and Dose Adjustment

Successful cannabis dosing requires patience and systematic titration. Most UK prescribers recommend the following approach:

Week 1-2: Start at the lowest recommended dose, typically taken in the evening to monitor tolerance. Keep a detailed symptom diary noting effects, side effects, and symptom changes.

Week 3 onwards: If well-tolerated and insufficient symptom relief, increase the dose by the smallest increment available (usually 2.5-5mg). Wait 3-7 days between increases, allowing time to assess the new dose’s effect.

Target dose finding: Continue titration until you achieve adequate symptom control or reach a dose where further increases cause unacceptable side effects. Most patients plateau at a “sweet spot” before higher doses are needed.

Maintenance: Once established on an effective dose, maintain consistency. Some patients find their optimal dose changes seasonally or during disease flares.

Cannabis for Inflammation and Symptom Management

The therapeutic potential of cannabis in Crohn’s disease centres on several mechanisms. CBD and THC both possess anti-inflammatory properties, with research suggesting they may reduce intestinal inflammation through multiple pathways including immune regulation and barrier function improvement.

Beyond inflammation, cannabis often helps manage associated symptoms: abdominal pain and cramping improve with both compounds; appetite stimulation—important given Crohn’s-related malnutrition—is particularly associated with THC; diarrhoea management may improve through anti-motility effects; sleep disturbance, common in Crohn’s, often responds to cannabinoid treatment; and mood and anxiety symptoms frequently improve.

However, cannabis should complement, not replace, conventional Crohn’s disease management with gastroenterologists and specialist IBD nurses. Learn more about medical cannabis in the UK to understand the current evidence and regulatory position.

When to Speak With Your Gastroenterologist or Prescriber

Regular communication with your healthcare team is essential. Contact your prescriber if:

Side effects develop or worsen (dizziness, drowsiness, dry mouth, coordination issues)
Expected symptom improvement doesn’t occur within 2-3 weeks at a given dose
New symptoms appear or existing Crohn’s symptoms worsen
You’re considering pregnancy or breastfeeding
Drug interactions occur with new medications
You’re considering stopping cannabis treatment
Disease flares necessitate hospitalisation

Legal Status in the UK

Medical cannabis remains a controlled drug in the UK. Legal access requires prescription from a specialist registered with the General Medical Council who believes cannabis is appropriate for your condition. Unlicensed products may be prescribed in certain circumstances, but all prescribers must adhere to strict regulatory guidelines. Ensure you’re only obtaining cannabis through legitimate NHS or registered private prescriptions.

Medical Disclaimer

This guide provides educational information only and does not constitute medical advice. Cannabis affects individuals differently. Always consult with qualified healthcare professionals before starting, adjusting, or stopping cannabis treatment. Pregnant women, breastfeeding mothers, and those with certain medical conditions should avoid cannabis. This content is current as of publication but medical guidance evolves; verify information with your healthcare provider. Never self-medicate with unregulated cannabis products.